Doma Perpetual Capital Management LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed September 10, 2024), Doma Perpetual Capital Management LLC reported 9 stock positions worth $150.3 million. Its top holding was Davita (DVA) at 46.4% of the portfolio, followed by Liberty Media Corp.-Liber-New (LSXMK, 12.0%) and Pacira Biosciences (PCRX, 11.3%). Compared with Q4 2023, it opened 1 new position, added to 3 and reduced 1. The biggest buy was Inmode (INMD, shares +381%) and the biggest sale Davita (DVA, shares −0%).
- Most Recent 13F
- Q2 2026
- Location
- Miami, FL
- CIK
- 0001962221
- Portfolio Value
- $150.3M (Q1 2024)
- SEC Filing
- 0001172661-24-004075 ↗ filed Sep 10, 2024
Holdings Value
Holdings 9 stocks · $150.3M
| DVA Davita Inc. | 46.42% | 505,481 | $69.8M | Reduce -0.2% |
| LSXMK Liberty Media Corp.-Liber-New | 11.96% | 605,107 | $18.0M | Add +37.1% |
| PCRX Pacira Biosciences Inc. | 11.32% | 582,440 | $17.0M | Add +212.6% |
| INMD Inmode Ltd. | 9.31% | 647,399 | $14.0M | Add +381.4% |
| NSSC Napco Security Technologies | 5.33% | 199,514 | $8.0M | No change |
| HIFS Hingham Institution for SVGS | 4.49% | 38,734 | $6.8M | New |
| BBD Banco Bradesco-ADR | 4.23% | 2,225,588 | $6.4M | No change |
| AFYA Afya Ltd. Class A | 3.64% | 294,909 | $5.5M | No change |
| BABA Alibaba Group Holding-SP ADR | 3.30% | 68,500 | $5.0M | No change |
Portfolio Sells Q4 2023 → Q1 2024
| DVA Davita Inc. | Reduce -0.2% | 46.42% | −5.90 |
Portfolio Buys Q4 2023 → Q1 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $430.8M | PCRX, NOMD, MBIN, INMD, HIFS |
| Q1 2026 | 11 | $372.4M | PCRX, DVA, MBIN, INMD, AFYA |
| Q4 2025 | 12 | $355.6M | PCRX, INMD, MBIN, NOMD, DVA |
| Q3 2025 | 12 | $297.8M | PCRX, NSSC, DVA, INMD, SIRI |
| Q2 2025 | 10 | $264.0M | BBD, PCRX, DVA, NSSC, INMD |
| Q1 2025 | 10 | $254.4M | PCRX, DVA, INMD, BBD, NSSC |
| Q4 2024 | 8 | $201.0M | INMD, PCRX, SIRI, BBD, NSSC |
| Q3 2024 | 8 | $198.0M | INMD, BBD, NSSC, SIRI, PCRX |
| Q2 2024Amended | 9 | $215.6M | DVA, INMD, PCRX, BBD, LSXMK |
| Q1 2024Amended | 9 | $150.3M | DVA, LSXMK, PCRX, INMD, NSSC |